News Headlines

  1. Top Employer 2025: Rottendorf Pharma Receives International Award 9/28/2026

    Rottendorf Pharma has been recognized as a Top Employer 2025 in Germany. The Top Employer Institute, headquartered in Amsterdam, has assessed and certified more than 2,400 companies in 125 countries. 

  2. New Gerteis Roller Compactors: Rottendorf Pharma Invests Millions In State-Of-The-Art Technology 9/28/2026

    Rottendorf Pharma has commissioned a new dry granulation system from Swiss manufacturer Gerteis Maschinen + Processengineering AG at its Ennigerloh site.

  3. Rottendorf Pharma To Double Long-Term Manufacturing Capacity With New Campus 9/28/2026

    Rottendorf Pharma has officially begun construction of the Rottendorf Campus in Oelde, Germany, a major investment aimed at expanding manufacturing capacity for the global pharmaceutical industry.

  4. 4basebio And TriLink BioTechnologies Partner To Advance Leading Pharmaceutical Company's Phase I Cell Therapy Program 9/28/2026

    4basebio PLC, a specialist in enzymatically-produced DNA for new genetic medicines, announces they will supply clinical-grade opDNA starting material for a multi-national pharmaceutical innovator’s (“the Client”) latest cell therapy program.

  5. LIB Therapeutics And Sun Pharma Announce Global Licensing, Commercialization And Manufacturing Agreement For Lerodalcibep, A Novel PCSK9 Inhibitor, Ex-US And China; Lerodalcibep (Lyrokaul®) Approved In The EU 9/28/2026

    Sun Pharmaceutical Industries Limited (together with its subsidiaries and/or associated companies, “Sun Pharma”) and LIB Therapeutics Inc. (“LIB”) today announced: An exclusive licensing agreement granting Sun Pharma rights to commercialize and manufacture lerodalcibep worldwide, excluding the United States and China.

  6. Future Fields Closes Oversubscribed $8M Series A to Turn Flies Into Bioreactors That Address Undruggable Diseases 9/26/2026
  7. Nanexa And Novo Enter Into EUR 1.165 Billion Global License And Collaboration Agreement For Long-Acting Injectables 9/24/2026

    Nanexa AB (publ) (“Nanexa”), a Swedish drug delivery platform company developing long-acting injectable drugs based on its proprietary PharmaShell technology platform, today announces that it has entered into a global exclusive license and collaboration agreement with Novo Nordisk (“Novo”) for the use of the PharmaShell technology platform for certain peptide-based drugs targeting obesity, type 2 diabetes and other cardiometabolic indications.

  8. Minaris And Asimov Partner To Advance AAV Manufacturing With OXGENE Technology 9/24/2026

    Minaris, a global cell and gene therapy (CGT) CDMO and multimodal biosafety testing organization, and Asimov, the company building an AI-native synthetic biology platform to advance therapeutic development, today announced a partnership that enables higher performing producer cell lines for production of adeno-associated virus (AAV) gene therapies.

  9. Recipharm Partners With CanVirex To Advance Oncolytic Virus Therapy 9/24/2026

    Recipharm, a leading global contract development and manufacturing organisation (CDMO), and CanVirex, a Swiss biotechnology company developing next-generation oncolytic virus immunotherapies, today announced a process development collaboration to support the scale-up of CanVirex's Vero cell/measles virus manufacturing platform.

  10. Amberstone Biosciences And Henlius Enter Into Collaboration And License Agreement For Conditionally Activated T-Cell Engagers For Solid Tumors 9/24/2026

    Amberstone Biosciences, Inc., a preclinical-stage oncology company developing pH-gated, tumor-activated T-cell engagers (TCEs), today announced a collaboration and license agreement with Shanghai Henlius Biotech, Inc., a commercial-stage biopharmaceutical company (2696.HK).